Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01927731 · ClinicalTrials.gov registry record · Phase 2
Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT01927731: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01927731 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 48 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01927731, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.
Interventions
- OTHER Laboratory Biomarker Analysis
- DRUG Eltrombopag Olamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2013-10-14 |
| Est. Completion | 2023-06-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01927731
The ClinicalTrials.gov registry entry for NCT01927731 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Laboratory Biomarker Analysis is the first listed.
NCT01927731 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01927731 about?
NCT01927731 is a clinical study titled "Eltrombopag Olamine in Increasing Platelet Counts in Patients Undergoing Transplant". This phase II trial studies how well eltrombopag olamine works in increasing platelet counts in patients undergoing transplant. Eltrombopag olamine may help platelet counts and the immune system recover from blood or bone marrow transplant.
What is the current status of trial NCT01927731?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2013-10-14. Estimated completion is 2023-06-06.
What interventions are being tested in trial NCT01927731?
The interventions under investigation include: Laboratory Biomarker Analysis (OTHER), Eltrombopag Olamine (DRUG).
Who is sponsoring clinical trial NCT01927731?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.